To study outcomes in patients of relapsed and cancer that has spread to other body parts or organs in carcinoma of cervix, post chemotherapy treatment.
Not Applicable
- Conditions
- Health Condition 1: C53- Malignant neoplasm of cervix uteri
- Registration Number
- CTRI/2021/12/038486
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age >18 years with histopathologically confirmed upfront metastatic cervical patients or patients with cervical cancer who have become metastatic/recurred/progressed after prior concurrent chemo radiation or radiation.
Exclusion Criteria
a. Oligometastatic cervical cancer patients who are planned for treatment with curative intent.
b. Patients treated with palliative radiotherapy only.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progressionTimepoint: To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progression
- Secondary Outcome Measures
Name Time Method I.To estimate the Overall tumour response rates including stable disease, partial response, complete response and progressive disease. <br/ ><br>II.Toxicities of therapy: To study the toxicities and tolerance to chemotherapy/bevacizumab/immunotherapy. <br/ ><br>III.To estimate the overall survival of patients with metastatic stage IVB/recurrent/persistent cervical cancer patients treated at our institute with palliative systemic therapy from January 2015 to March 2020. <br/ ><br>Timepoint: 6 months